Literature DB >> 15091208

Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.

Ashok R Shaha1.   

Abstract

OBJECTIVES/HYPOTHESIS: The outcome in differentiated thyroid cancer generally depends on the stage of the disease at the time of presentation; prognostic factors such as age, grade, size, extension, or distant metastasis; and risk groups (eg, low or high risk). The author has reviewed a large number of patients with differentiated thyroid cancer to analyze their hypothesis and to confirm that various risk groups have a major implication in relation to extent of the treatment and outcome. Differentiated thyroid cancers make up 90% of all thyroid tumors. The prognostic factors are well defined, such as age, size of the tumor, extrathyroidal extension, presence of distant metastasis, histological appearance, and grade of the tumor. The author has previously divided the risk groups into low-, intermediate-, and high-risk categories based on prognostic factors. The study describes the author's treatment approach related to the extent of thyroidectomy and adjuvant therapy based on various risk groups and the long-term survival. STUDY
DESIGN: Retrospective.
METHODS: In a retrospective review of 1038 patients with differentiated thyroid carcinoma, various prognostic factors were studied by univariate and multivariate analysis. The significant prognostic factors were studied in detail and, based on these prognostic factors, the patients were divided into low-, intermediate- and high-risk groups. The survival curves were plotted by Kaplan-Meier method.
RESULTS: The long-term survivals in low-, intermediate- and high-risk groups were 99%, 87%, and 57% respectively. Based on these risk groups, a decision tree was made regarding extent of thyroidectomy and adjuvant treatment. In the high-risk group and selected patients in the intermediate-risk group, aggressive surgery including removal of all gross disease and extrathyroidal extension with postoperative radioactive iodine ablation is recommended. In the low-risk group and selected patients in the intermediate-risk group, lobectomy appears to be satisfactory with excellent long-term outcome. The surgical treatment offers the best long-term results in low-risk patients, and the role of adjuvant treatment in this group is questionable.
CONCLUSION: The decisions in the management of well-differentiated thyroid cancer should be based on various prognostic factors and risk groups. The long-term survival in the low-risk group is excellent, and consideration should be given to conservative surgical resection depending on the extent of the disease. In the high-risk group and selected patients in the intermediate-risk group, total thyroidectomy with radioactive ablation is warranted. A consideration may be given to external-beam radiation therapy in selected high-risk patients. It is apparent, based on the author's clinical experience and critical retrospective analysis, that the author's hypothesis that risk groups are extremely important in the long-term outcome of patients with differentiated thyroid cancer is correct. Based on various risk groups, the author currently is able to guide the treatment policies for thyroid cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15091208     DOI: 10.1097/00005537-200403000-00001

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  65 in total

1.  Off-site evaluation of three-dimensional ultrasound for the diagnosis of thyroid nodules: comparison with two-dimensional ultrasound.

Authors:  Soo Chin Kim; Ji-Hoon Kim; Seung Hong Choi; Tae Jin Yun; Jae Yeon Wi; Sun Ah Kim; Hye Young Sun; Inseon Ryoo; Sun-Won Park; Chul-Ho Sohn
Journal:  Eur Radiol       Date:  2016-01-22       Impact factor: 5.315

2.  Surgical decision making in the management of well-differentiated thyroid cancer.

Authors:  Natalya Chernichenko; Ashok R Shaha
Journal:  Indian J Surg Oncol       Date:  2012-05-01

3.  Conservative management of well-differentiated thyroid cancer.

Authors:  Mazen Hassanain; Marvin Wexler
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

4.  Video-assisted thyroidectomy: report of a 7-year experience in Rome.

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Pietro Princi; Carmela De Crea; Rocco Bellantone
Journal:  Langenbecks Arch Surg       Date:  2006-03-10       Impact factor: 3.445

5.  Level IIb lymph node metastasis in thyroid papillary carcinoma.

Authors:  Yusuf Vayisoglu; Cengiz Ozcan; Ozgur Turkmenoglu; Kemal Gorur; Murat Unal; Ahmet Dag; Koray Ocal
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-07       Impact factor: 2.503

6.  Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?

Authors:  Ian Ganly; Iain J Nixon; Laura Y Wang; Frank L Palmer; Jocelyn C Migliacci; Ahmad Aniss; Mark Sywak; Antoine E Eskander; Jeremy L Freeman; Michael J Campbell; Wen T Shen; Fernanda Vaisman; Denise Momesso; Rossana Corbo; Mario Vaisman; Ashok Shaha; R Michael Tuttle; Jatin P Shah; Snehal G Patel
Journal:  Thyroid       Date:  2015-08-12       Impact factor: 6.568

7.  Preoperative ultrasound evaluation of laterocervical lymph nodes: timing and experience modify the treatment of patients with differentiated thyroid cancer.

Authors:  Marica Grasso; Alessandro Puzziello; Maurizio De Palma
Journal:  Updates Surg       Date:  2019-01-02

8.  Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern Thailand.

Authors:  Tada Yipintsoi; Teerapon Premprabha; Alan Geater; Tanyaluck Thientunyakij; Suchitra Thongmak
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

9.  Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes.

Authors:  Mohamed Abdelgadir Adam; Paul Speicher; John Pura; Michaela A Dinan; Shelby D Reed; Sanziana A Roman; Julie A Sosa
Journal:  Ann Surg Oncol       Date:  2014-06-17       Impact factor: 5.344

10.  Prognostic factors in patients with multiple recurrences of well-differentiated thyroid carcinoma.

Authors:  Theresa Holler; Jenna Theriault; Richard J Payne; Jonathan Clark; Spiro Eski; Jeremy L Freeman
Journal:  J Oncol       Date:  2009-10-15       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.